Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Avanafil + tamsulosin** is a combination of two small molecule drugs, avanafil, a phosphodiesterase type 5 (PDE5) inhibitor, and tamsulosin, an alpha-1 adrenergic receptor antagonist. Avanafil is indicated for the treatment of erectile dysfunction in men by increasing blood flow to the penis via inhibition of PDE5, which increases cyclic GMP, leading to smooth muscle relaxation in the corpus cavernosum. Tamsulosin is indicated primarily for the treatment of benign prostatic hyperplasia (BPH), where it works by blocking alpha-1 adrenergic receptors in the prostate and bladder neck, relaxing smooth muscle and improving urine flow. This combination is not marketed as a fixed-dose product but could be prescribed concomitantly in clinical practice. Coadministration requires caution due to the risk of additive hypotensive effects. Both drugs are taken orally, but they are not formulated as a fixed combination medication and there is no brand name for the combined use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on avanafil + tamsulosin.